Literature DB >> 8449513

Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis.

A C Gough1, C A Smith, S M Howell, C R Wolf, S P Bryant, N K Spurr.   

Abstract

Using a combination of somatic cell hybrids, in situ hybridization, and linkage mapping, we have been able to localize the cytochrome P450 CYP2D6 gene to chromosome 22 in the region q13.1. Linkage analysis, using locus-specific primers, showed a maximum sex-average lod score of 8.12 (theta = 0.00) between the marker pH130 (D22S64) and CYP2D6, of 6.92 (theta = 0.00) between the marker KI839 (D22S95) and CYP2D6, and of 4.80 (theta = 0.036) between the platelet-derived growth factor beta subunit gene (PDGFB) and CYP2D6.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8449513     DOI： 10.1006/geno.1993.1082

Source DB:  PubMed          Journal:  Genomics        ISSN： 0888-7543            Impact factor:   5.736


  14 in total

Review 1.  Coprescription of tamoxifen and medications that inhibit CYP2D6.

Authors:  Kostandinos Sideras; James N Ingle; Matthew M Ames; Charles L Loprinzi; David P Mrazek; John L Black; Richard M Weinshilboum; John R Hawse; Thomas C Spelsberg; Matthew P Goetz
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

Review 2.  Genetics of Common Antipsychotic-Induced Adverse Effects.

Authors:  Raymond R MacNeil; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2016-05-20

Review 3.  Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.

Authors:  Mohd Sami Ur Rasheed; Abhishek Kumar Mishra; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2017-09-04       Impact factor: 3.996

Review 4.  Pharmacogenetics: the slow, the rapid, and the ultrarapid.

Authors:  U A Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

Review 5.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.

Authors:  S Panserat; C Mura; N Gérard; M Vincent-Viry; M M Galteau; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Hum Genet       Date:  1994-10       Impact factor: 4.132

Review 7.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype.

Authors:  S Panserat; C Mura; N Gérard; M Vincent-Viry; M M Galteau; E Jacoz-Aigrain; R Krishnamoorthy
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

9.  Clinical, cytogenetic, and molecular characterization of seven patients with deletions of chromosome 22q13.3.

Authors:  N J Nesslinger; J L Gorski; T W Kurczynski; S K Shapira; J Siegel-Bartelt; J P Dumanski; R F Cullen; B N French; H E McDermid
Journal:  Am J Hum Genet       Date:  1994-03       Impact factor: 11.025

10.  Management of postoperative nausea and vomiting: focus on palonosetron.

Authors:  Neil A Muchatuta; Michael J Paech
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.